Deucravacitinib uniquely binds to the TYK2 regulatory domain, which allows it to target the underlying pathogenesis of psoriasis through inhibition of the intracellular component of the IL-12, IL-23, and Type I interferon pathways [109,110]. This evidence concerns the gene IL23A and psoriasis.